Optimizing efficiencies and reducing white space across Phase I to Phase III in an oncology trial

A large biopharmaceutical had recently acquired a biotech company and was developing its leading molecules for the treatment of lymphoma. This case study shares how Fortrea supported the progression of one of the molecules from Phase I through Phase III, enabled process efficiencies across multiple studies and delivered results with significant time and cost savings.